Synthetic Approaches to Piperazine-Containing Drugs Approved by FDA in the Period of 2011-2023

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2024 Jan 11

PMID 38202651

Authors

Maria Novella Romanelli

Laura Braconi

Alessio Gabellini

Dina Manetti

Giambattista Marotta

Elisabetta Teodori

Affiliations

Soon will be listed here.

Abstract

The piperazine moiety is often found in drugs or in bioactive molecules. This widespread presence is due to different possible roles depending on the position in the molecule and on the therapeutic class, but it also depends on the chemical reactivity of piperazine-based synthons, which facilitate its insertion into the molecule. In this paper, we take into consideration the piperazine-containing drugs approved by the Food and Drug Administration between January 2011 and June 2023, and the synthetic methodologies used to prepare the compounds in the discovery and process chemistry are reviewed.

Citing Articles

Design, synthesis, analgesic, antibacterial and docking studies of novel 8-piperazinylcaffeine carboxylate ionic liquids.

Soltani Rad M, Behrouz S, Yazdi P, Hashemi S, Behrouz M RSC Adv. 2024; 14(39):28669-28683.

PMID: 39257660 PMC: 11384933. DOI: 10.1039/d4ra06244b.

Novel Piperazine Derivatives of Vindoline as Anticancer Agents.

Zsoldos B, Nagy N, Donko-Toth V, Keglevich P, Weber M, Dekany M Int J Mol Sci. 2024; 25(14).

PMID: 39063170 PMC: 11277489. DOI: 10.3390/ijms25147929.

References

Huang H, Tremont S, Lee L, Keller B, Carpenter A, Wang C . Discovery of potent, nonsystemic apical sodium-codependent bile acid transporter inhibitors (Part 2). J Med Chem. 2005; 48(18):5853-68. DOI: 10.1021/jm0402162. View

Siwek M, Wojtasik-Bakalarz K, Krupa A, Chrobak A . Brexpiprazole-Pharmacologic Properties and Use in Schizophrenia and Mood Disorders. Brain Sci. 2023; 13(3). PMC: 10046771. DOI: 10.3390/brainsci13030397. View

Vitaku E, Smith D, Njardarson J . Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among U.S. FDA approved pharmaceuticals. J Med Chem. 2014; 57(24):10257-74. DOI: 10.1021/jm501100b. View

Roth G, Heckel A, Colbatzky F, Handschuh S, Kley J, Lehmann-Lintz T . Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120). J Med Chem. 2009; 52(14):4466-80. DOI: 10.1021/jm900431g. View

He W, Zhang Z, Ma D . A Scalable Total Synthesis of the Antitumor Agents Et-743 and Lurbinectedin. Angew Chem Int Ed Engl. 2019; 58(12):3972-3975. DOI: 10.1002/anie.201900035. View

Agai-Csongor E, Domany G, Nogradi K, Galambos J, Vago I, Keseru G . Discovery of cariprazine (RGH-188): a novel antipsychotic acting on dopamine D3/D2 receptors. Bioorg Med Chem Lett. 2012; 22(10):3437-40. DOI: 10.1016/j.bmcl.2012.03.104. View

Fell J, Fischer J, Baer B, Blake J, Bouhana K, Briere D . Identification of the Clinical Development Candidate , a Covalent KRAS Inhibitor for the Treatment of Cancer. J Med Chem. 2020; 63(13):6679-6693. DOI: 10.1021/acs.jmedchem.9b02052. View

Lai Y . Small Molecule HIV-1 Attachment Inhibitors: Discovery, Mode of Action and Structural Basis of Inhibition. Viruses. 2021; 13(5). PMC: 8148533. DOI: 10.3390/v13050843. View

Kim E . Letermovir: First Global Approval. Drugs. 2017; 78(1):147-152. DOI: 10.1007/s40265-017-0860-8. View

10.

Kang C . Fosdenopterin: First Approval. Drugs. 2021; 81(8):953-956. DOI: 10.1007/s40265-021-01520-2. View

11.

Wendt M, Shen W, Kunzer A, McClellan W, Bruncko M, Oost T . Discovery and structure-activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo. J Med Chem. 2006; 49(3):1165-81. DOI: 10.1021/jm050754u. View

12.

Jiang Q, Li M, Li H, Chen L . Entrectinib, a new multi-target inhibitor for cancer therapy. Biomed Pharmacother. 2022; 150:112974. DOI: 10.1016/j.biopha.2022.112974. View

13.

Borsini F, Evans K, Jason K, Rohde F, Alexander B, Pollentier S . Pharmacology of flibanserin. CNS Drug Rev. 2002; 8(2):117-42. PMC: 6741686. DOI: 10.1111/j.1527-3458.2002.tb00219.x. View

14.

Alcantara Montero A, Pacheco de Vasconcelos S . Role of vortioxetine in the treatment of neuropathic pain. Rev Esp Anestesiol Reanim (Engl Ed). 2022; 69(10):640-648. DOI: 10.1016/j.redare.2022.09.003. View

15.

Soskic V, Sukalovic V, Kostic-Rajacic S . Exploration of N-arylpiperazine Binding Sites of D2 Dopaminergic Receptor. Mini Rev Med Chem. 2015; 15(12):988-1001. DOI: 10.2174/138955751512150731112448. View

16.

Souers A, Leverson J, Boghaert E, Ackler S, Catron N, Chen J . ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013; 19(2):202-8. DOI: 10.1038/nm.3048. View

17.

Hoffmann T, Bos M, Stadler H, Schnider P, Hunkeler W, Godel T . Design and synthesis of a novel, achiral class of highly potent and selective, orally active neurokinin-1 receptor antagonists. Bioorg Med Chem Lett. 2005; 16(5):1362-5. DOI: 10.1016/j.bmcl.2005.11.047. View

18.

Pahwa M, Sleem A, Elsayed O, Good M, El-Mallakh R . New Antipsychotic Medications in the Last Decade. Curr Psychiatry Rep. 2021; 23(12):87. DOI: 10.1007/s11920-021-01298-w. View

19.

Poratti M, Marzaro G . Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib. Eur J Med Chem. 2019; 172:143-153. DOI: 10.1016/j.ejmech.2019.03.064. View

20.

Shirley M . Avatrombopag: First Global Approval. Drugs. 2018; 78(11):1163-1168. DOI: 10.1007/s40265-018-0949-8. View